Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
*Delayed quote courtesy of Google Finance.
View Stock Information
Lookup Date :
- Jan 13, 2020 Marinus Provides Business Outlook for 2020
- Jan 07, 2020 Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference